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Abstract 
Background: Biannual mass azithromycin administration to preschool children reduces all-cause mortality, but the 
mechanism for the effect is not understood. Azithromycin has activity against malaria parasites, and malaria is a lead-
ing cause of child mortality in the Sahel. The effect of biannual versus annual azithromycin distribution for trachoma 
control on serological response to merozoite surface protein 1 (MSP-119), a surrogate for malaria incidence, was evalu-
ated among children in Niger.
Methods: Markers of malaria exposure were measured in two arms of a factorial randomized controlled trial 
designed to evaluate targeted biannual azithromycin distribution to children under 12 years of age compared to 
annual azithromycin to the entire community for trachoma control (N = 12 communities per arm). Communities 
were treated for 36 months (6 versus 3 distributions). Dried blood spots were collected at 36 months among children 
ages 1–5 years, and MSP-119 antibody levels were assessed using a bead-based multiplex assay to measure malaria 
seroprevalence.
Results: Antibody results were available for 991 children. MSP-119 seropositivity was 62.7% in the biannual distribu-
tion arm compared to 68.7% in the annual arm (prevalence ratio 0.91, 95% CI 0.83 to 1.00). Mean semi-quantitative 
antibody levels were lower in the biannual distribution arm compared to the annual arm (mean difference − 0.39, 
95% CI − 0.05 to − 0.72).
Conclusions: Targeted biannual azithromycin distribution was associated with lower malaria seroprevalence com-
pared to that in a population that received annual distribution.
Trial Registration Clinicaltrials.gov NCT00792922
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Background
Biannual mass azithromycin administration has been 
shown to decrease all-cause post-neonatal child mortal-
ity in some settings in sub-Saharan Africa [1, 2]. Annual 
mass azithromycin distribution to entire communities is 
highly effective at clearing the ocular strains of chlamydia 
that cause blinding trachoma [3–5]. Since 1999, over 750 
million doses of azithromycin have been distributed to 
trachoma-endemic districts [6, 7]. Mass drug administra-
tion (MDA) with azithromycin as part of trachoma elimi-
nation programmes has been shown to reduce the burden 
of other childhood infections, including diarrhoea [8], 
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lower respiratory infection [9], and in some studies 
malaria [10, 11], possibly contributing to observed reduc-
tions in child mortality [12, 13].
Azithromycin has modest activity against Plasmodium 
falciparum, the most virulent human malaria parasite, 
due to action against the parasite apicoplast [14–17]. Pre-
vious studies assessing the effect of azithromycin MDA 
on malaria infection yielded contradictory conclusions. 
In Tanzania, malaria prevalence decreased transiently in 
the month following azithromycin MDA [11]. Previously, 
in the Partnership for the Rapid Elimination of Tra-
choma (PRET)-Niger study, lower malaria parasitaemia 
prevalence was documented in communities that had 
received two biannual azithromycin MDAs compared to 
communities receiving one annual MDA [10]. However, 
there was no difference in parasitaemia after 36 months 
of biannual versus annual MDA [18, 19]. These stud-
ies measured malaria infection via thick smear, 6 to 
12 months after the last antibiotic dose, when trachoma 
measurements are typically performed in trachoma tri-
als. The effect of a single dose of azithromycin for malaria 
would likely occur over a shorter time period, and thus 
a single measure of malaria infection many months after 
treatment may not be an ideal measure of the overall 
effect of azithromycin on malaria incidence. Thick smear 
will also not detect low-intensity infections [20]. Alterna-
tive measures of malaria exposure and transmission may 
therefore be useful in evaluating the effect of azithromy-
cin for malaria as an off-target effect of azithromycin for 
trachoma control.
Antibody measurements have been proposed as mark-
ers of malaria exposure over time [21–23]. Population 
seroprevalence to merozoite surface protein 1 (MSP-1), 
a dominant antigen of asexual P. falciparum, is predicted 
to provide information about malaria incidence beyond 
point prevalence by integrating serologic responses at 
different time points [21–25]. While serologic mark-
ers are not direct measures of clinical burden, they pro-
vide seroprevalence and age-seroprevalence curves give 
insights into exposure and transmission patterns [22, 25]. 
Here, the effect of biannual distribution of azithromycin 
to children was compared to annual distribution to the 
entire community, each over three years, on the burden 
of malaria using serologic markers of P. falciparum expo-
sure in preschool-aged children in Niger.
Methods
Ethical approval
Ethical approval was obtained from the Committee on 
Human Research at the University of California, San 
Francisco and the Comité d’Ethique du Niger. Verbal 
informed consent was obtained from local chiefs of each 
study community and from the parent or guardian of 
each study participant. CDC staff did not have contact 
with study personnel or access to personal identifying 
information and were determined to not be engaged in 
human subjects research.
Study design
PRET was a series of community-randomized trials in 
Niger, The Gambia, and Tanzania designed to assess mass 
azithromycin distribution strategies for trachoma control 
(clinicaltrials.gov NCT00792922). In the present report, 
data from the Niger trial only were included [26–28]. The 
Niger trial was a 2 × 2 factorial trial of standard versus 
enhanced coverage and annual versus biannual distri-
bution of azithromycin for trachoma control. In Niger, 
communities were randomized to one of four arms in a 
1:1:1:1 fashion: (1) annual treatment of all individuals in 
the community with a treatment coverage target of 80%; 
(2) annual treatment of all individuals in the community 
with an enhanced treatment coverage target of 90%; (3) 
biannual treatment of children aged 12 and under with 
a treatment coverage target of 80%; or (4) biannual treat-
ment of children aged 12 and under with an enhanced 
treatment coverage target of 90%. Communities were 
randomized by stratified block randomization within 
each Centre de Santé Intégrée (CSI) by high or low tra-
choma prevalence, as previously described [26]. The 
present report is restricted only to the enhanced cover-
age arms, as dried blood spots for antibody tested were 
only collected in these arms. The remainder of this report 
is, therefore, focused only on the enhanced distribution 
study arms. Communities were eligible for inclusion in 
the study if they had a population between 250 and 600 
at the most recent government census (done in 2001 with 
population sizes in 2010 estimated based on projected 
population growth) and clinical trachoma prevalence of 
at least 10% at the time of the census.
Study setting
Study communities were located in Matamèye District, 
Zinder Region and were treated from May 2010 until 
May 2013. This region is situated in the Sahel and has 
highly seasonal malaria incidence, with peak transmis-
sion shortly after the peak in rainfall, typically in Sep-
tember [29, 30]. At the time of the study, there was no 
seasonal malaria chemoprevention programme in this 
region, although a bed net distribution programme was 
active. Annual distributions occurred in June/July, at the 
beginning of the high transmission season. In the bian-
nual distribution arm, communities were additionally 
treated in December/January, during the low transmis-
sion season. Data for the present analysis was collected in 
September 2013.
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Intervention
Prior to each MDA, a door-to-door enumerative cen-
sus was undertaken in all study communities, which 
formed the sampling frame for treatment and evaluation. 
In all communities included in this report, each MDA 
occurred over a 1-to-4-day period: up to three follow-up 
visits occurred after the initial MDA day in an attempt to 
achieve coverage of 90% or greater. In the annual MDA 
arm, communities received a total of three rounds of 
MDA distributed via a door-to-door program to all indi-
viduals, regardless of age. In the biannual MDA com-
munities, children aged 6  months to 12  years received 
a total of six rounds of door-to-door MDA; no one over 
the age of 12 was treated in these communities. During 
each MDA, all eligible participants were offered a single 
dose of directly observed oral azithromycin (20  mg/kg 
up to a maximum dose of 1 g in adults). Children under 
6  months of age or those with macrolide allergy were 
offered topical tetracycline ointment (1%) for 6 weeks. In 
the annual treatment arm, pregnant women were offered 
tetracycline ointment.
Serology assessment
In each study community, a random sample of 50 chil-
dren aged 0 to 5 years were selected to have samples col-
lected. Dried blood spots were only collected in children 
age 1 to 5  years of age due to the presence of maternal 
antibodies. Blood samples were collected via finger or 
heel stick in September 2013. Dried blood spots based 
on the most recent census [31] were analysed for anti-
body response to a portion of the P. falciparum antigen 
MSP-119 using a multiplex bead array assay on a Luminex 
200 platform. Results were reported as the median fluo-
rescence intensity (MFI) minus background (MFI-BG), 
where background is the signal from beads with buffer 
only. The seropositivity cutoff was MFI-BG ≥ 1758 as 
determined by receiver operator characteristic curve 
analysis using a positive panel of serum from individuals 
with malaria slides positive for P. falciparum and a nega-
tive panel of serum from US-residents who had never 
travelled to a malaria-endemic region.
Clinical and laboratory assessments
Blood samples from the children who contributed dried 
blood spots were also tested for P. falciparum infection 
using microscopy. Thick blood smears were stained 
with 3% Giemsa, and each slide was read by two expe-
rienced microscopists at the Zinder Regional Hospi-
tal. Discrepancies were adjudicated by a third reader. 
Microscopists determined the presence or absence 
of P. falciparum parasites and counted the number of 
asexual parasites per 200 white blood cells (assuming 
a white blood cell count of 8000/μl). Each child’s tym-
panic temperature was assessed at the time of blood 
collection. Clinically symptomatic malaria was defined 
as a blood slide positive for P. falciparum accompa-
nied by tympanic temperature ≥ 38.5 °C. The geometric 
mean of the two parasite densities was used for analy-
sis. Haemoglobin concentration was measured for all 
children (HemoCue AB, Ängelholm, Sweden).
Sample size
The trial was powered for the primary trachoma out-
come [26]. An a priori sample size calculation was 
not performed for this non-prespecified secondary 
outcome.
Statistical methods
All analyses were conducted as intention-to-treat. 
Descriptive statistics were calculated by study arm 
with medians and interquartile ranges (IQR) or pro-
portions. A  log10 transformations of MFI-BG (as a 
semi-quantitative indicator of antibody levels) and par-
asite density was used for analysis. Parasite prevalence, 
clinically symptomatic malaria prevalence, and sero-
prevalence of MSP-119-specific antibodies and corre-
sponding binomial 95% confidence intervals (CI) were 
calculated at the community level. Prevalence ratios 
(PR) for the association between malaria infection and 
MSP-119 seropositivity were calculated using general-
ized linear mixed models with a binomial distribution 
and log link with a random effect for the study commu-
nity to account for clustering within communities, and 
adjusted for age and gender [32, 33].
To assess the difference in seropositivity to MSP-1 by 
study arm, generalized linear mixed model with a bino-
mial distribution and log link were used to estimate 
risk ratios, with a random effect for study community. 
To assess differences in quantitative antibody levels, a 
 log10 transformation of the MSP-1 MFI-BG values was 
used. Generalized linear mixed models with a Gaussian 
distribution and identity link were used to estimate the 
mean difference in antibody level between study arms, 
with a random effect for study community. Differences 
in the age-seroprevalence and semi-quantitative anti-
body curves were evaluated to assess differences in 
short- and long-term malaria exposure in a generalized 
linear model with binomial (seropositivity) or Gauss-
ian (MFI-BG) distribution, with a study arm by age 
category interaction term, with age treated as a con-
tinuous variable. All analyses were conducted in R (ver-
sion 3.4.3, The R Foundation for Statistical Computing, 
Vienna, Austria).
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Results
A total of 991 children contributed MSP-119 serologic 
data, of whom 460 were in annual azithromycin distri-
bution communities and 531 in biannual azithromycin 
distribution communities (Fig.  1). The distribution of 
participant and baseline community characteristics was 
balanced between study arms (Table  1). Median age 
of children selected for sample collection was 3  years, 
Niger: 6 CSIs in Matameye 
District
Excluded (n=0)
♦ Not meeting inclusion criteria (n=0) 
♦ Declined to participate (n=0 ) 
Clusters analyzed (n=12 communities)
Participants analyzed 
460 children aged 1-5 months at 36 months
Excluded from analysis (n=0 communities)
Lost to follow-up, Month 36 (n=0)
Discontinued intervention, Month 36 (n=0) 
Annual Treatment (n=12 communities)
Total treated/total censused children
• Month 0: 1733/1814
• Month 12: 1512/1629
• Month 24: 1551/1664
• Month 36: 1329/1459
♦ Did not receive allocated intervention (n=0)
Lost to follow-up. Month 36 (n=0)
Discontinued intervention, Month 36 (n=0) 
Biannual Treatment (n=12 communities)
Total treated/total censused children
• Month 0: 1531/1635
• Month 6: 1382/1501
• Month 12: 1365/1462
• Month 18: 1403/1509
• Month 24: 1357/1492
• Month 30: 1312/1433
• Month 36: 1200/1315
♦ Did not receive allocated intervention (n=0)
Clusters analyzed (n=12 communities)
Participants analyzed 
531 children aged 1-5 months at 36 months
Excluded from analysis (n=0 communities)
Allocation
Analysis
Follow-Up
Randomized (n= 48
communities)
Enrollment
Randomized to other arms 
(n= 24 communities)
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram for included communities and individuals
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with an equal distribution of children of age 1–5  years. 
Azithromycin MDA coverage in the study communities 
has been previously reported and exceeded 90% among 
children aged 6–59 months at each time point [18].
In September 2013 at the 36-month study visit, half of 
the children (55.2%, 95% CI 52.1 to 58.3%) had a posi-
tive thick smear for malaria parasites, and prevalence 
of malaria was 7.0% (95% CI 5.5 to 8.7%). As previously 
reported, there were no significant differences in malaria 
infection or clinically symptomatic malaria prevalence by 
study arm [18, 19]. Seropositivity against MSP-119 was 
65.5% (95% CI 62.5% to 68.4%). The prevalence of malaria 
infection and seropositivity increased with increasing 
age (PR 1.09 per one-year increase in age, 95% CI 1.06 to 
1.13, P < 0.001), but the prevalence of clinically sympto-
matic malaria did not (PR 1.14 per 1-year increase in age, 
95% CI 0.95 to 1.36, P = 0.16). Figure  2 shows the rela-
tionship between malaria seroprevalence and infection 
and parasite density and mean MSP-119 titre. MSP-119 
seropositivity was higher among children with malaria 
infection (PR 1.23, 95% CI 1.04 to 1.44, P = 0.01) com-
pared to those without infection, but not among those 
with clinically symptomatic malaria (PR = 1.20, 95% CI 
0.70 to 1.59, P = 0.19) compared to those without clini-
cally symptomatic malaria.
MSP-119 seroprevalence was 9% lower (PR 0.91, 95% 
CI 0.83 to 1.00, P = 0.047) among 1–5-year-olds from 
communities in which children received biannual treat-
ment compared to those from communities receiv-
ing annual treatment. Mean MFI-BG was also lower in 
1–5-year-olds in biannual MDA communities than chil-
dren in communities receiving annual MDA (mean dif-
ference − 0.17, 95% CI − 0.02 to − 0.32, P = 0.04) (Fig. 3). 
There was no evidence that malaria exposure differed by 
age as assessed by age-seroprevalence (P = 0.94, age-by-
arm interaction; Fig. 3) or MFI-BG by age curve (P = 0.35, 
age-by-arm interaction) between children in communi-
ties receiving biannual versus annual azithromycin.
Discussion
Biannual distribution of azithromycin targeted to chil-
dren was associated with lower antibody-based measures 
of exposure to P. falciparum compared to annual distri-
bution to the entire community. In these same commu-
nities, no difference in P. falciparum infection prevalence 
after 36 months of treatment was reported [18]. The anti-
body response to MSP-119 is long-lived [22] and is poten-
tially a more sensitive indicator than microscopy point 
prevalence of cumulative malaria incidence. Thus, these 
results suggest that serologic markers of malaria expo-
sure were slightly lower in areas receiving biannual com-
pared to annual treatment with azithromycin.
The small (9%) reduction in MSP-119 seropreva-
lence documented in this study between biannually 
Table 1 Descriptive characteristics of communities (at baseline) and children providing dried blood spots for serologic 
assessments (at 36 months)
Study arm Biannual azithromycin Annual azithromycin
Community characteristics
 No. communities 12 12
 No. children/community, mean 66 (range 36 to 124) 72 (range 37 to 119)
 Proportion female,  % (95% CI) 49.0% (45.1 to 52.9) 52.1% (49.3 to 54.8)
 Age, months (95% CI) 18.7 (17.4 to 19.9) 18.4 (17.3 to 19.4)
Individual characteristics
 No. individuals 531 460
  Age, years
   1 113 (21%) 99 (22%)
   2 105 (20%) 87 (19%)
   3 89 (17%) 84 (18%)
   4 113 (21%) 86 (19%)
   5 111 (21%) 104 (23%)
 Female gender 275 (52%) 231 (50%)
 P. falciparum infection 291 (55%) 256 (56%)
 Clinically symptomatic P. falciparum infection plus fever 33 (6%) 36 (8%)
 P. falciparum parasite density, median (IQR) 60 (0 to 1340) 100 (0 to 2960)
 P. falciparum parasite density among children with infection, median (IQR) 1100 (240 to 5815) 2320 (470 to 8030)
 Haemoglobin, g/dL, median (IQR) 9.5 (8.4 to 10.4) 9.4 (8.2 to 10.5)
 MSP-119 seroprevalence 333 (63%) 316 (69%)
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and annually treated communities diverges from previ-
ous reports that have indicated a 44 to 73% decrease in 
malaria infection prevalence 1 month after azithromycin 
treatment [11, 34]. Compared with short-term effects 
of azithromycin on malaria infection, more modest 
reductions in antibody-based measures of P. falciparum 
exposure would be expected since the outcomes reflect 
differences in cumulative exposure between groups, aver-
aged over a longer period of time. However, the intensity 
of transmission in holoendemic regions may make it dif-
ficult to detect differences in malaria seropositivity, par-
ticularly as children age and their probability of previous 
exposure increases. In holoendemic settings, short-acting 
interventions may also have less effect on transmission 
due to the ubiquity of infection. Among young children in 
particular, antibody responses may be lost, which could 
affect sensitivity to seasonal trends [35, 36]. The results 
of this study suggest that longer-term effects of azithro-
mycin for malaria may be more modest than short-term 
effects.
Azithromycin has modest in vitro activity against P. fal-
ciparum due to targeting the plasmodial apicoplast [15, 
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16, 37], and thus a reduction in malaria burden is a plau-
sible mechanism for the reduction in mortality observed 
following azithromycin distribution [1, 12, 13, 38]. In the 
same study area as the present analysis, biannual mass 
azithromycin distribution led to a reduction in mortal-
ity due to infection causes among preschool children. 
No difference in mortality due to malaria was noted, but 
this assessment was based on verbal autopsy [38], which 
can suffer from misclassification and poor sensitivity for 
malaria diagnosis [39, 40]. Additionally, the study was not 
powered to detect a difference in malaria-specific mor-
tality. The results shown here suggest that malaria inci-
dence is impacted by additional doses of azithromycin, 
which may indicate that reduction in malaria contributes 
to observed decreases in all-cause mortality following 
azithromycin distribution. However, the precise mecha-
nism of action for the observed reduction in mortality 
following azithromycin distribution remains unclear. 
Some evidence suggests that the effect of azithromycin 
on malaria prevalence is transient [41]. Azithromycin 
likely also leads to reductions in other pathogenic organ-
isms which may contribute to overall mortality effects. 
For example, the prevalence of Campylobacter species, 
an important cause of diarrhea and diarrhea-related 
mortality, was reduced in children in communities 
receiving biannual azithromycin compared to placebo 
in Niger [42]. Any effect of azithromycin on mortal-
ity that is mediated via changes in malaria transmission 
likely occurs in the context of alteration of transmission 
of other pathogenic organisms, and the overall effect of 
azithromycin distribution on mortality may or may not 
be due in part to small changes in malaria transmission.
The results of this study must be considered in the con-
text of several limitations. First, there was no untreated 
control group, and thus the quantitative impact of 
azithromycin distribution cannot be determined. Second, 
biannual treatment of children under age 12 was com-
pared to annual treatment of all individuals in the com-
munity, and so did not compare biannual versus annual 
treatment in the same age group. Third, mass azithromy-
cin distributions occurred at the beginning of the high 
transmission season and the low transmission season. 
Malaria transmission is highly seasonal in Niger, and 
treatment targeted specifically during the high transmis-
sion season may have had a larger effect than treatment 
during the low transmission season. However, a single 
dose of azithromycin during the high transmission sea-
son may also paradoxically have reduced effect compared 
to treatment during the low transmission season due to 
the high parasite load and frequency of infection during 
the high transmission season [43]. Fourth, the generaliza-
bility of these results is limited only to preschool children 
in the setting of highly seasonal malaria transmission. 
Future studies could evaluate the impact of azithromycin 
MDA on malaria incidence in older children or adults.
Conclusions
The results of this study are consistent with a small 
reduction in P. falciparum exposure in communities in 
Niger receiving targeted biannual azithromycin in chil-
dren compared to those receiving annual azithromycin 
distribution to entire communities. Thus, mass treatment 
with azithromycin may lead to a decrease in malaria inci-
dence in young children, presumably contributing to the 
survival benefits afforded by azithromycin.
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